210
Participants
Start Date
July 23, 2013
Primary Completion Date
September 3, 2014
Study Completion Date
September 3, 2014
AKB-6548
Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Placebo
Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Glendale
Tucson
Azusa
Chula Vista
Downey
El Centro
La Mesa
Long Beach
Riverside
Sacramento
San Diego
Arvada
Westminster
Lauderdale Lakes
Port Charlotte
Tampa
Augusta
Macon
Meridian
Evergreen Park
Lafayette
Shreveport
Detroit
Lansing
Petoskey
Pontiac
Farmington
Kansas City
Las Vegas
Albuquerque
Flushing
Mineola
New Rochelle
Rosedale
Asheville
Charlotte
Rocky Mount
Wilmington
Cincinnati
Columbia
Knoxville
Arlington
Austin
Edinburg
Houston
San Antonio
St. George
Lead Sponsor
Akebia Therapeutics
INDUSTRY